Predicted protein targets (top 12)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.45 |
| ▸ | SMN1; SMN2 | Q16637 | 3/20 | 0.44 |
| ▸ | KDM4E | B2RXH2 | 2/20 | 0.44 |
| ▸ | HRH3 | Q9Y5N1 | 7/20 | 0.43 |
| ▸ | ESR1 | P03372 | 3/20 | 0.42 |
| ▸ | ESR2 | Q92731 | 1/20 | 0.42 |
| ▸ | RECQL | P46063 | 1/20 | 0.40 |
| ▸ | GAA | P10253 | 1/20 | 0.40 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.39 |
| ▸ | MEN1 | O00255 | 1/20 | 0.39 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.39 |
| ▸ | LTA4H | P09960 | 1/20 | 0.39 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL2825357 | 0.90 | CYP2C19 (0.45) | ALDH1A1SMN1; SMN2KDM4EMAPK1MEN1 | |
| SCHEMBL2824616 | 0.82 | SMN1; SMN2 (0.43) | ALDH1A1SMN1; SMN2KDM4EHRH3GAA | |
| SCHEMBL2825371 | 0.80 | HRH3 (0.45) | ALDH1A1SMN1; SMN2KDM4EHRH3RECQL | |
| SCHEMBL2825283 | 0.79 | ALDH1A1 (0.40) | ALDH1A1SMN1; SMN2MEN1KMT2A | |
| SCHEMBL2823208 | 0.72 | ALDH1A1 (0.37) | ALDH1A1SMN1; SMN2KDM4EMEN1KMT2A | |
| SCHEMBL2826040 | 0.71 | HCRTR1 (0.46) | ALDH1A1SMN1; SMN2MAPK1MEN1KMT2A | |
| SCHEMBL2824676 | 0.69 | CYP2C19 (0.44) | ALDH1A1KDM4EHRH3MEN1KMT2A | |
| SCHEMBL7947916 | 0.67 | LTA4H (0.73) | ALDH1A1SMN1; SMN2KDM4EESR1ESR2 | |
| SCHEMBL31326504 | 0.67 | CYP2C19 (0.43) | ALDH1A1SMN1; SMN2KDM4EHRH3RECQL | |
| SCHEMBL21978241 | 0.66 | ESR1 (0.39) | ALDH1A1SMN1; SMN2KDM4EHRH3ESR1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 8 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1773827-B1 | BENZOTHIAZOLE DERIVATIVES | HOFFMANN LA ROCHE (CH) | 2010-02-17 | — | — | EP | disclosed |
| US-7371749-B2 | Benzothiazole derivatives | HOFFMANN-LA ROCHE INC. (US) | 2008-05-13 | — | — | US | disclosed |
| US-7371749-B2 | Benzothiazole derivatives | HOFFMANN-LA ROCHE INC. (US) | 2008-05-13 | — | — | US | disclosed |
| US-7371749-B2 | Benzothiazole derivatives | HOFFMANN-LA ROCHE INC. (US) | 2008-05-13 | — | — | US | disclosed |
| EP-1773827-A1 | BENZOTHIAZOLE DERIVATIVES | F.HOFFMANN-LA ROCHE AG (CH) | 2007-04-18 | — | — | EP | disclosed |
| US-20060019949-A1 | Benzothiazole derivatives | HOFFMANN-LA ROCHE INC. | 2006-01-26 | — | — | US | disclosed |
| WO-2006008041-A1 | BENZOTHIAZOLE DERIVATIVES | F. HOFFMANN-LA ROCHE AG (CH) | 2006-01-26 | — | — | WO | disclosed |
| WO-2006008041-A1 | BENZOTHIAZOLE DERIVATIVES | F. HOFFMANN-LA ROCHE AG (CH) | 2006-01-26 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20060019949-A1 | Benzothiazole derivatives | CNR2, CNR1, CHRNA2 | ALDH1A1 146/4885SMN1; SMN2 162/4885KDM4E 1202/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.